Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2002 5
2003 6
2004 7
2005 6
2006 10
2007 17
2008 6
2009 13
2010 19
2011 40
2012 37
2013 41
2014 43
2015 41
2016 48
2017 34
2018 32
2019 39
2020 47
2021 65
2022 41
2023 36
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

564 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Benson AB, et al. Among authors: sharma s. J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021. J Natl Compr Canc Netw. 2018. PMID: 29632055 Free PMC article.
Role of Dietary Supplements in Thyroid Diseases.
Dahiya V, Vasudeva N, Sharma S, Kumar A. Dahiya V, et al. Among authors: sharma s. Endocr Metab Immune Disord Drug Targets. 2022;22(10):985-996. doi: 10.2174/1871530322666220419125131. Endocr Metab Immune Disord Drug Targets. 2022. PMID: 35440339 Review.
Oxidative Stress: Major Threat in Traumatic Brain Injury.
Khatri N, Thakur M, Pareek V, Kumar S, Sharma S, Datusalia AK. Khatri N, et al. Among authors: sharma s. CNS Neurol Disord Drug Targets. 2018;17(9):689-695. doi: 10.2174/1871527317666180627120501. CNS Neurol Disord Drug Targets. 2018. PMID: 29952272 Review.
Response.
Sharma S, Stansbury R. Sharma S, et al. Chest. 2022 Sep;162(3):e154-e155. doi: 10.1016/j.chest.2022.05.022. Chest. 2022. PMID: 36088108 No abstract available.
Response.
Sharma S, Billings ME, Cohen RT. Sharma S, et al. Chest. 2021 Apr;159(4):1691-1692. doi: 10.1016/j.chest.2020.11.036. Epub 2021 Apr 6. Chest. 2021. PMID: 34022013 No abstract available.
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Benson AB, et al. Among authors: sharma s. J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061. J Natl Compr Canc Netw. 2018. PMID: 30006429 Free PMC article.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Among authors: sharma s. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
Editorial: Reviews in radiation oncology.
Lee DY, Sudhandiran G, Sharma SD. Lee DY, et al. Among authors: sharma sd. Front Oncol. 2023 Sep 6;13:1283431. doi: 10.3389/fonc.2023.1283431. eCollection 2023. Front Oncol. 2023. PMID: 37746255 Free PMC article. No abstract available.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: sharma s. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
564 results